Ibrutinib
- PDF / 169,762 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 7 Downloads / 175 Views
1
S
Atrial fibrillation: 3 case reports In a single centre study of 24 patients conducted in Australia between 1 April 2015 and 30 June 2017, three patients [ages and sexes not stated] were described, who developed atrial fibrillation (AF) during treatment with ibrutinib for haematological malignancies. The patients had been receiving oral ibrutinib [dosage not stated]. One of these 3 patients had a mild valvular disease without significant systolic dysfunction. Subsequently, all three patients developed AF [duration of treatment to reaction onset not stated]. All three patients were treated with a rate control strategy. One of these three patient’s ibrutinib was transiently withheld following the onset of the AF with no effect on it. During follow-up of 18 months after AF diagnosis, the patient was hospitalised because of symptomatic AF with rapid ventricular response [not all outcomes stated]. Author comment: "Cardiologists need to be aware of the increased risk of AF in patients receiving ibrutinib". "In the AF group, only one patient had mild valvular disease. . .Only one patient had ibrutinib transiently withheld following onset of AF without any effect on it.""[O]nly one (25%) patient required hospitalization due to symptomatic AF with rapid ventricular response." Ezad S, et al. Ibrutinib-related atrial fibrillation: A single center Australian experience. Asia-Pacific Journal of Clinical Oncology 15: e187-e190, No. 5, Oct 2019. Available from: URL: http://doi.org/10.1111/ajco.13179 803435943 Australia
0114-9954/19/1780-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 23 Nov 2019 No. 1780
Data Loading...
